
Journal Menu
► ▼ Journal Menu-
- Current Oncology Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal Browser-
arrow_forward_ios
Forthcoming issue
arrow_forward_ios Current issue - Volumes not published by MDPI
Need Help?
Announcements
2 October 2023
MDPI Insights: The CEO's Letter #4 - MDPI Presence in China

Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Open Access in China
It is Saturday, 23 September, and I have just returned from an unforgettable 12-day trip to China, visiting our main offices in Beijing and Wuhan. In the wake of a packed and very enjoyable agenda of internal and external meetings, I would like to use this edition of the CEO Letter to showcase how MDPI supports the scholarly community in China.
Coincidentally, Jack McKenna, Communications Associate from MDPI’s corporate content team, has just released a blog article discussing China’s open access (OA) policy. It is a timely read, providing a concise overview of the development of the OA movement in China and reflecting on its future. I shall draw some content from Jack’s piece and use this edition of the CEO Letter to highlight the various ways in which MDPI is involved in this market. And it would be remiss of me not to include some pictures and highlights from my travels!
Open Access Policy in China
As per Jack’s post, in 2020, China became the world’s leading producer of research articles. Today, China is experiencing a “substantial growth rate in OA [Open Access] publication”. This growth is supported by the State’s commitment to research & development and its policy “requiring the promotion of open science”.
Over the past two decades, there have been gradual developments in China’s OA framework, with repositories and platforms being developed in a consistent manner. Currently, key institutions across China – including the National Science Library, the National Science and Technology Library, and the Natural Science Foundation of China – support OA. The State aims to establish consistent policies across government agencies – a framework for a more encompassing embrace of OA across institutions.
In China, the number of subscription-only articles decreased by nearly 30% over the 10-year period of 2011–2021, while gold OA increased by 22%. Between 2017 and 2020 alone, China published 800,921 academic papers in an OA format.
In 2023, as the leading publisher of academic research, China is pursuing “self-reliance”. Therefore, the State will be establishing consistent policies across government agencies, including those related to OA. Additionally, it will want to ensure that Chinese people can access the research that is supported by Chinese funding and produced by Chinese academics. For this reason, “Open Access is a matter of priority in China”.
MDPI Offices in China
While the history of MDPI begins in Basel, Switzerland, the story of MDPI’s founder is very much rooted in China. Dr. Shu-kun Lin, Founder and President of MDPI, graduated with a BSc from Wuhan University in 1982. He also studied physical chemistry at the Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences (1982–1986; MSc in 1985), and at the University of Louisville, USA (1987–1989). Dr. Lin completed his doctorate in organic chemistry at the Swiss Federal Institute of Technology (ETH-Zürich) in 1992.
Stefan Tochev (CEO, MDPI) at MDPI’s Wuhan office.
In 2002, MDPI’s Basel headquarters moved to Matthäusstrasse 11, 4052 Basel, and Dr. Lin opened an editorial office in Qingdao, China, which launched the journal Marine Drugs in the following year. Below is a list of MDPI’s current offices in China and their respective dates of inauguration:
- 2008: Beijing (Tongzhou, Haidian)
- 2013: Wuhan (Hankou, Guanggu)
- 2019: Tianjin
- 2021: Dalian
- 2021: Nanjing
Our Strength is in Our People
With over 6,000 MDPI staff, across 20 offices in 11 countries, MDPI is able to offer authors responsive and efficient round-the-clock support, enabling a rapid publication process.
In my experience, stakeholders are genuinely surprised when they realize the extent of our global operations. My response is to reiterate that our people are our strength. This is why we have fast and efficient processes and top-notch responsiveness. Our global presence ensures that your manuscript is constantly attended to, rather than sitting on someone’s desk. We prioritize our authors’ needs and act quickly to move things through the various stages of publication. MDPI is built on speed, convenience, and competence, which I believe are core pillars for success in any industry. We continually strive to improve our systems and processes on the basis of these core strengths. We literally have over 6,000 staff worldwide dedicated to serving your needs. It’s not magic: it’s people; it’s real.
Impactful Research
MDPI Awards
To support the academic community, and especially young researchers, and also to enhance communication among scientists, MDPI journals offer various awards in specific fields. We serve the scientific community by funding research to facilitate the development of sustainable global solutions through our annual World Sustainability Award and Emerging Sustainability Leader Award.
In 2022, MDPI made awards totalling over US$1 million in recognition and support of researchers worldwide.
Across our journal catalogue, we have granted over 2,000 awards to recognize and support researchers from all disciplines. Since 2016, these awards have served as a source of recognition, acknowledging the impact of research by heightening the influence of talented individuals. The award types mainly include the Young Investigator Award, the Best PhD Thesis Award, the Best Paper Award, and the Outstanding Reviewer Award.
To learn more about MDPI Awards and to find out which are currently available, please click here.
MDPI Awards to Scholars from China
Since 2021, there have been 23 Best Paper Awards granted to authors affiliated with Chinese institutions, identifying their papers as having high-quality scientific impact. A total of 45 Chinese scholars have received awards such as the Young Investigator Award, the Best PhD Thesis Award, the Outstanding Reviewer Award, and the Tu Youyou Award, among others. Prizes for these awards include MDPI grants for paid publications, totalling over CHF 70,000 for scholars affiliated with Chinese institutions.
MDPI’s Tu Youyou Award
Prof. Tu Youyou (left), Dr. Shu-Kun Lin (President, MDPI).
In 2015, Professor Tu Youyou was awarded the Nobel Prize in Physiology or Medicine “for her discoveries concerning a novel therapy against Malaria.” In order to commemorate Professor Tu’s contributions to human health and to promote the passion and spirit conveyed by her experiences, MDPI in 2016 established the ‘Tu Youyou Award’, which runs biennially to recognize outstanding scholars dedicated to the research of natural products and medicinal chemistry.
The 2022 Tu Youyou Award was granted to Prof. Dr. Xiaoguang Lei of Peking University. Click here to access the interview with the winner.
2015 Nobel Prize for Medicine Awarded to Professor Youyou Tu
Professor Tu’s work was celebrated in a Special Issue from Molecules on the occasion of her 80th birthday. The Special Issue: 'Artemisinin (Qinghaosu): Commemorative Issue in Honor of Professor Youyou Tu on the Occasion of her 80th Anniversary” was created five years before she won the Nobel Prize, highlighting the visibility MDPI provides researchers and their work.
Highly Cited Articles by Chinese Scholars Published in MDPI
Click here to access the most cited MDPI papers published by scholars affiliated with Chinese institutions. This list presents the most influential research from the more than 287,000 MDPI papers published by Chinese scholars. With over 9 million total citations, I encourage you to maximize your visibility and impact by publishing with MDPI, the number one most cited open access publisher.
Read more:
- Tu Youyou Award
- World Sustainability Awards
- Available Awards
Inside MDPI
Stefan Tochev (CEO, MDPI) with the Beijing Marketing team.
Marketing Department in China
During my visit to our offices in Beijing and Wuhan, I had the opportunity to meet with, and to present to, our local marketing teams. These teams are responsible for various journal-related and corporate promotional activities, including newsletters, conferences, seminars, author training, journal awards, content creation, digital marketing, and social media.
I was pleased by the ambition and curiosity of our marketing colleagues. They showed a strong desire to collaborate and acquire knowledge and tactics to effectively market and promote MDPI-journal-related activities. I presented some of the principles and objectives that we apply in the Corporate Marketing and Communications department, and used the opportunity to strengthen our collaborative communications across offices.
Stefan Tochev (CEO, MDPI) with the Wuhan Marketing team.
Coming Together for Science
Collaborations, Scholarships and Meetings
MDPI maintains partnerships with nearly 190 learned societies and over 800 institutions and consortia, helping to facilitate the transition to OA publishing. Our commitment to working with institutions is evident in China, where we have successfully established over 35 Institutional Open Access Programs (IOAP) with esteemed institutions such as the Tsinghua University, Huazhong University of Science and Technology, and Shanghai Jiao Tong University.
Our institutional partnerships, waiver programs, and article processing cost discounts create diverse pathways to OA publishing for researchers worldwide.
Scholarships in China
Since 2021, several MDPI journals (Sensors, Photonics, Coatings, Materials, Energies, and Journal of Fungi) have funded full scholarships for four Master’s and five Ph.D. projects in China. These scholarships align with Tianjin University, Wuhan University of Technology, Central South University, the Chinese Academy of Sciences, and the China University of Petroleum (Beijing).
Meeting with the Society of Chinese University Journals (CUJS)
Prof. Tieming Zhang (President of CUJS, centre) and MDPI colleagues at CUJS office.
I am pleased to have participated in some highly productive meetings during my visit to China, including one with the Society of Chinese University Journals (CUJS). The meeting involved Prof. Tieming Zhang (President of CUJS), Assoc. Prof. Xin Zhang (Vice President and Secretary General), and Dr. Fei Gao (Executive Member of CUJS). Alongside my colleagues Dr. Guoshi Liu, Dr. Giulia Stefenelli, and Anita Sun, I represented MDPI and held an open discussion to address any questions regarding OA and MDPI.
We discussed several methods for collaboration, including a workshop on the future of peer review, MDPI sponsoring a funding grant for early-career researchers, and transitioning journals from diamond to gold OA. I am thankful for the opportunity to have met our colleagues at CUJS in person and feel very confident about our future collaborations in support of OA publishing in China.
MDPI hosts free academic seminars, author training sessions, and academic conferences as part of its commitment to enrich and support the scholarly community. CUJS often stages academic events (e.g., conferences, editor training, and editor competitions), and I believe there are great opportunities for CUJS and MDPI to collaborate accordingly.
Meeting with National Science Library, Chinese Academy of Sciences (NSLC)
Stefan Tochev (CEO, MDPI), Dr. Giulia Stefenelli (Chair of Scientific Officers, MDPI), Anita Sun (PR Manager, MDPI) and Dr. Guoshi Liu (Managing Director, MDPI) at the National Science Library, Chinese Academy of Sciences.
We also visited the NSLC Director, Xiwen Liu, and colleagues Ying Jin, Zhesi Shen, and Sichao Tong. Following our introductions, we gave a presentation on the history and editorial process at MDPI, discussing specific details related to MDPI’s business and data. We highlighted the status of our IOAP collaborations in China and the makeup of our author base, specifically in China, and drew attention to the fact that MDPI has published research by authors from every country in the world. We then discussed the design indicators, calculation methods and implementation purposes of the ‘Early Warning Journal List’ and how we can have open communication to provide any data regarding MDPI journals. I am pleased to report that we reached a consensus on future communications, and am grateful to NSLC for hosting us in their offices.
In-person meetings with stakeholders provide an invaluable opportunity to communicate what MDPI is about and the various ways in which we serve the scholarly community. While digital marketing and online communication are essential, they are no replacement for the understanding and trust that come about through in-person interactions.
The Numbers
As at September 2023, China holds the largest position in MDPI’s global market, ranking as the largest contributor to the total number of papers published by MDPI.
At this point in time, there were more than 847,000 China mainland scholars who have published with MDPI, 51 of whom are Section-Editors-in-Chief (SEiC) of MDPI journals, with seven serving as Editors-in-Chief (EiCs) for journals such as Air, Big Data and Cognitive Computing, Blockchains, Future, Nanoenergy Advances, and Targets.
Our growth and presence in China are a true testament to the service we provide to the scholarly community, and to the relationships we foster through collaborative activities. We look forward to continuing to support the growth of the scholarly community in China, providing a valuable and trusted experience with MDPI.
Closing Thoughts
Final Reflections on our MDPI Offices in Beijing and Wuhan
Stefan Tochev (CEO, MDPI), Dr. Constanze Schelhorn (Indexing Manager, MDPI), Jiale Shang (Admin, Tongzhou, MDPI) at Beijing Capital International Airport, Beijing.
I spent approximately two weeks visiting some of our offices in China, and the first word that comes to mind when describing my experience is ‘hospitality.’ My colleagues and I were met with enthusiasm and delight at the airport by the Tongzhou Admin team (thank you, Jiale Shang, and thank you, Eric Wang, for keeping us organized on this trip!) and were taken care of with great attention. From hotels to transportation, dinners, and meetings, our stay was catered for perfectly.
Perhaps this is where MDPI’s focus on customers and service originates. At our core, we are a service company that provides a publishing platform for its authors. It’s therefore no surprise that authors consistently rate their experience with MDPI very highly.
95% of submitting authors rate their overall experience with the MDPI publication process as Excellent or Good (Springer Nature report 90%).
91% of submitting authors rate their overall experience with the MDPI peer review process as Excellent or Good.
Speed/Efficiency and Editorial Relationship are two key reasons underlying this high satisfaction score. ‘Editorial Relationship’ can be further explored, but in the past month, the most commonly noted aspects were the professionalism, kindness, availability, communicativeness, and personalized assistance provided by our editorial staff throughout the process. These attributes are at the core of our work across all our offices and continents.
Hospitality and Service
Just as our Chinese colleagues strove to keep us engaged by showing us the city sights (thank you, Thea Pan, and Jason Wu from the Wuhan Marketing team!) and sharing a variety of wonderful meals, our editorial staff are committed to serving our authors throughout their publishing journey. Our aim is to place the author at the centre of everything we do, eager to welcome our ‘guests’ and provide them with a pleasant publishing experience.
I asked my colleague Francis Wu (Senior Publisher, Wuhan office) where this hospitality originates. He responded that it is part of Chinese culture. I reflected long and deep on this answer. China is a vast country, and when visitors arrive, hosts want to ensure they feel welcomed and taken care of in order to maximize their time and visit. I can’t think of a better analogy for how I would want our authors to feel when they visit MDPI for their publishing needs. A company culture that prioritizes service, something that goes beyond products and productivity, and focuses on the overall experience. Over 6,000 people, across all MDPI offices, are ready, willing and able to go the extra mile for their colleagues and their customers. This is something I am truly proud of.
Chief Executive Officer
MDPI AG
28 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Breast Cancer”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Breast Cancer” shown below:
1. “Applying Deep Learning for Breast Cancer Detection in Radiology”
by Ella Mahoro and Moulay A. Akhloufi
Curr. Oncol. 2022, 29(11), 8767–8793; https://doi.org/10.3390/curroncol29110690
Available online: https://www.mdpi.com/1718-7729/29/11/690
2. “Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?”
by Liqin Yao, Gang Jia, Lingeng Lu and Wenxue Ma
Curr. Oncol. 2022, 29(7), 4902–4913; https://doi.org/10.3390/curroncol29070389
Available online: https://www.mdpi.com/1718-7729/29/7/389
3. “Optimizing Adjuvant Treatment Recommendations for Older Women with Biologically Favorable Breast Cancer: Short-Course Radiation or Long-Course Endocrine Therapy?”
by Susan G. R. McDuff and Rachel C. Blitzblau
Curr. Oncol. 2023, 30(1), 392–400; https://doi.org/10.3390/curroncol30010032
Available online: https://www.mdpi.com/1718-7729/30/1/32
4. “Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program”
by Nicoletta Staropoli, Elena Geuna, Gaetana Rinaldi, Giancarlo Bisagni, Vieri Scotti, Giovanni Faggioni, Laura Vannini, Carlo Arcara, Gabriella Moretti, Marco Gunnellini et al.
Curr. Oncol. 2022, 29(9), 6635–6641; https://doi.org/10.3390/curroncol29090521
Available online: https://www.mdpi.com/1718-7729/29/9/521
5. “Are Columnar Cell Lesions the Earliest Non-Obligate Precursor in the Low-Grade Breast Neoplasia Pathway?”
by Sarah Strickland and Gulisa Turashvili
Curr. Oncol. 2022, 29(8), 5664–5681; https://doi.org/10.3390/curroncol29080447
Available online: https://www.mdpi.com/1718-7729/29/8/447
6. “Efficacy and Accuracy of Using Magnetic Seed for Preoperative Non-Palpable Breast Lesions Localization: Our Experience with Magseed”
by Anna D’Angelo, Charlotte Marguerite Lucille Trombadori, Flavia Caprini, Stefano Lo Cicero, Valentina Longo, Francesca Ferrara, Simone Palma, Marco Conti, Antonio Franco, Lorenzo Scardina et al.
Curr. Oncol. 2022, 29(11), 8468–8474; https://doi.org/10.3390/curroncol29110667
Available online: https://www.mdpi.com/1718-7729/29/11/667
7. “Prevalence and Persistence of Anxiety and Depression over Five Years since Breast Cancer Diagnosis—The NEON-BC Prospective Study”
by Catarina Lopes, Luisa Lopes-Conceição, Filipa Fontes, Augusto Ferreira, Susana Pereira, Nuno Lunet and Natália Araújo
Curr. Oncol. 2022, 29(3), 2141–2153; https://doi.org/10.3390/curroncol29030173
Available online: https://www.mdpi.com/1718-7729/29/3/173
8. “Preoperative Radio(Chemo)Therapy in Breast Cancer: Time to Switch the Perspective?”
by Angel Montero and Raquel Ciérvide
Curr. Oncol. 2022, 29(12), 9767–9787; https://doi.org/10.3390/curroncol29120768
Available online: https://www.mdpi.com/1718-7729/29/12/768
28 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Oncology Nursing”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Oncology Nursing” shown below:
1. “Equity-Oriented Healthcare: What It Is and Why We Need It in Oncology”
by Tara C. Horrill, Annette J. Browne and Kelli I. Stajduhar
Curr. Oncol. 2022, 29(1), 186–192; https://doi.org/10.3390/curroncol29010018
Available online: https://www.mdpi.com/1718-7729/29/1/18
2. “A Continuing Educational Program Supporting Health Professionals to Manage Grief and Loss”
by Mary Jane Esplen, Jiahui Wong, Mary L. S. Vachon and Yvonne Leung
Curr. Oncol. 2022, 29(3), 1461–1474; https://doi.org/10.3390/curroncol29030123
Available online: https://www.mdpi.com/1718-7729/29/3/123
3. “Risk Stratification and Cancer Follow-Up: Towards More Personalized Post-Treatment Care in Canada”
by Robin Urquhart, Wendy Cordoba, Jackie Bender, Colleen Cuthbert, Julie Easley, Doris Howell, Julia Kaal, Cynthia Kendell, Samantha Radford and Jonathan Sussman
Curr. Oncol. 2022, 29(5), 3215–3223; https://doi.org/10.3390/curroncol29050261
Available online: https://www.mdpi.com/1718-7729/29/5/261
4. “Oncology Healthcare Professionals’ Mental Health during the COVID-19 Pandemic”
by Leeat Granek and Ora Nakash
Curr. Oncol. 2022, 29(6), 4054–4067; https://doi.org/10.3390/curroncol29060323
Available online: https://www.mdpi.com/1718-7729/29/6/323
5. “Lessons Learned from the Implementation of a Person-Centred Digital Health Platform in Cancer Care”
by Saima Ahmed, Karine LePage, Renata Benc, Guy Erez, Alon Litvin, Annie Werbitt, Gabrielle Chartier, Carly Berlin and Carmen G. Loiselle
Curr. Oncol. 2022, 29(10), 7171–7180; https://doi.org/10.3390/curroncol29100564
Available online: https://www.mdpi.com/1718-7729/29/10/564
27 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Psychosocial Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Psychosocial Oncology” shown below:
1. “The Chemo-Gut Pilot Study: Associations between Gut Microbiota, Gastrointestinal Symptoms, and Psychosocial Health Outcomes in a Cross-Sectional Sample of Young Adult Cancer Survivors”
by Julie M. Deleemans, Faye Chleilat, Raylene A. Reimer, Mohamad Baydoun, Katherine-Ann Piedalue, Dana E. Lowry, Jan-Willem Henning and Linda E. Carlson
Curr. Oncol. 2022, 29(5), 2973-2994; https://doi.org/10.3390/curroncol29050243
Available online: https://www.mdpi.com/1718-7729/29/5/243
2. “The Psychosocial Impact of COVID-19 on Older Adults with Cancer: A Rapid Review”
by Ridhi Verma, Heather M. Kilgour and Kristen R. Haase
Curr. Oncol. 2022, 29(2), 589-601; https://doi.org/10.3390/curroncol29020053
Available online: https://www.mdpi.com/1718-7729/29/2/53
3. “Assessing the Relationship between Socioeconomic Status, Race, and Psychological Distress in Cancer Survivors: A Population Based Study”
by Ikechukwu Chidobem, Fan Tian, Chisom Mgbodile, Francis Mgbodile, Tahereh Orouji Jokar, Esther Ogbuokiri and Nazia Khan
Curr. Oncol. 2022, 29(4), 2575-2582; https://doi.org/10.3390/curroncol29040211
Available online: https://www.mdpi.com/1718-7729/29/4/211
4. “Psychosocial Implications of COVID-19 on Head and Neck Cancer”
by Sarah M. Dermody and Andrew G. Shuman
Curr. Oncol. 2022, 29(2), 1062-1068; https://doi.org/10.3390/curroncol29020090
Available online: https://www.mdpi.com/1718-7729/29/2/90
5. “Biopsychosocial Markers of Body Image Concerns in Patients with Head and Neck Cancer: A Prospective Longitudinal Study”
by Justine G. Albert, Christopher Lo, Zeev Rosberger, Saul Frenkiel, Michael Hier, Anthony Zeitouni, Karen Kost, Alex Mlynarek, Martin Black, Christina MacDonald et al.
Curr. Oncol. 2022, 29(7), 4438-4454; https://doi.org/10.3390/curroncol29070353
Available online: https://www.mdpi.com/1718-7729/29/7/353
6. “Psychological Problems among Head and Neck Cancer Patients in Relation to Utilization of Healthcare and Informal Care and Costs in the First Two Years after Diagnosis”
by Florie E. van Beek, Femke Jansen, Rob J. Baatenburg de Jong, Johannes A. Langendijk, C. René Leemans, Johannes H. Smit, Robert P. Takes, Chris H. J. Terhaard, José A. E. Custers, Judith B. Prins et al.
Curr. Oncol. 2022, 29(5), 3200-3214; https://doi.org/10.3390/curroncol29050260
Available online: https://www.mdpi.com/1718-7729/29/5/260
7. “Screening for Distress and Health Outcomes in Head and Neck Cancer”
by Bryan Gascon, Aliza A. Panjwani, Olivia Mazzurco and Madeline Li
Curr. Oncol. 2022, 29(6), 3793-3806; https://doi.org/10.3390/curroncol29060304
Available online: https://www.mdpi.com/1718-7729/29/6/304
8. “Oncology Healthcare Professionals’ Mental Health during the COVID-19 Pandemic”
by Leeat Granek and Ora Nakash
Curr. Oncol. 2022, 29(6), 4054-4067; https://doi.org/10.3390/curroncol29060323
Available online: https://www.mdpi.com/1718-7729/29/6/323
26 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Hematology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Hematology” below:
1. “Primary Diffuse Large B-Cell Lymphoma of the Urinary Bladder: Update on a Rare Disease and Potential Diagnostic Pitfalls”
by Magda Zanelli, Francesca Sanguedolce, Maurizio Zizzo, Andrea Palicelli, David Pellegrini, Sabrina Farinacci, Alessandra Soriano, Elisabetta Froio, Luigi Cormio, Giuseppe Carrieri et al.
Curr. Oncol. 2022, 29(2), 956–968; https://doi.org/10.3390/curroncol29020081
Available online: https://www.mdpi.com/1718-7729/29/2/81
2. “Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology”
by Evgenii Shumilov, Paolo Mazzeo, Martin S. Zinkernagel, Myriam Legros, Naomi Porret, Lorenz Romagna, Detlef Haase, Georg Lenz, Urban Novak, Yara Banz et al.
Curr. Oncol. 2022, 29(2), 766–776; https://doi.org/10.3390/curroncol29020065
Available online: https://www.mdpi.com/1718-7729/29/2/65
3. “Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients”
by Isacco Ferrarini, Francesca Gandini, Ettore Zapparoli and Antonella Rigo
Curr. Oncol. 2022, 29(4), 2792–2797; https://doi.org/10.3390/curroncol29040227
Available online: https://www.mdpi.com/1718-7729/29/4/227
4. “The Use of Virtual Care in Patients with Hematologic Malignancies: A Scoping Review”
by Adam Suleman, Abi Vijenthira, Alejandro Berlin, Anca Prica and Danielle Rodin
Curr. Oncol. 2022, 29(2), 892–900; https://doi.org/10.3390/curroncol29020076
Available online: https://www.mdpi.com/1718-7729/29/2/76
by Margaret E. Stalker and Tomer M. Mark
Curr. Oncol. 2022, 29(7), 4464–4477; https://doi.org/10.3390/curroncol29070355
Available online: https://www.mdpi.com/1718-7729/29/7/355
6. “Concurrent Waldenstrom’s Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation”
by Peter A. DeRosa, Kyle C. Roche, Victor E. Nava, Sunita Singh, Min-Ling Liu and Anita Agarwal
Curr. Oncol. 2022, 29(7), 4587–4592; https://doi.org/10.3390/curroncol29070363
Available online: https://www.mdpi.com/1718-7729/29/7/363
7. “Diffuse Large B Cell Lymphoma Arising in Patients with Preexisting Hodgkin Lymphoma”
by Emilio Bellitti, Pierluigi Masciopinto, Pellegrino Musto, Elena Arcuti, Luca Mastracci, Giuseppina Opinto, Sabino Ciavarella, Attilio Guarini, Gerardo Cazzato, Giorgina Specchia et al.
Curr. Oncol. 2022, 29(9), 6115–6124; https://doi.org/10.3390/curroncol29090480
Available online: https://www.mdpi.com/1718-7729/29/9/480
8. “Total Body Irradiation for Hematopoietic Stem Cell Transplantation: What Can We Agree on?”
by Mitchell Sabloff, Steven Tisseverasinghe, Mustafa Ege Babadagli and Rajiv Samant
Curr. Oncol. 2021, 28(1), 903–917; https://doi.org/10.3390/curroncol28010089
Available online: https://www.mdpi.com/1718-7729/28/1/89
9. “Primary Vitreoretinal Lymphoma: Current Diagnostic Laboratory Tests and New Emerging Molecular Tools”
by Beatrice Melli, Pietro Gentile, Davide Nicoli, Enrico Farnetti, Stefania Croci, Fabrizio Gozzi, Elena Bolletta, Luca De Simone, Francesca Sanguedolce, Andrea Palicelli et al.
Curr. Oncol. 2022, 29(10), 6908–6921; https://doi.org/10.3390/curroncol29100543
Available online: https://www.mdpi.com/1718-7729/29/10/543
10. “Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment”
by Matthew Ho, Alexander Xiao, Dongni Yi, Saurabh Zanwar and Giada Bianchi
Curr. Oncol. 2022, 29(11), 8975–9005; https://doi.org/10.3390/curroncol29110705
Available online: https://www.mdpi.com/1718-7729/29/11/705
26 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Surgical Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Surgical Oncology” below:
1. “Outcomes of Enhanced Recovery after Surgery (ERAS) in Gynecologic Oncology: A Review”
by Steven P. Bisch and Gregg Nelson
Curr. Oncol. 2022, 29(2), 631–640; https://doi.org/10.3390/curroncol29020056
Available online: https://www.mdpi.com/1718-7729/29/2/56
2. “Systemic Therapy and Its Surgical Implications in Patients with Resectable Liver Colorectal Cancer Metastases. A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference”
by Shahid Ahmed, Nicholas Bosma, Michael Moser, Shahida Ahmed, Bryan Brunet, Janine Davies, Corinne Doll, Dorie-Anna Dueck, Christina A. Kim, Shuying Ji et al.
Curr. Oncol. 2022, 29(3), 1796–1807; https://doi.org/10.3390/curroncol29030147
Available online: https://www.mdpi.com/1718-7729/29/3/147
3. “Challenges in Geriatric Oncology—A Surgeon’s Perspective”
by Ruth Parks and Kwok-Leung Cheung
Curr. Oncol. 2022, 29(2), 659–674; https://doi.org/10.3390/curroncol29020058
Available online: https://www.mdpi.com/1718-7729/29/2/58
4. “The Prediction of Survival after Surgical Management of Bone Metastases of the Extremities—A Comparison of Prognostic Models”
by Ofir Gal Ben, Terrence Chi Fang Soh, Sarah Vaughan, Viswanath Jayasanker, Ashish Mahendra and Sanjay Gupta
Curr. Oncol. 2022, 29(7), 4703–4716; https://doi.org/10.3390/curroncol29070373
Available online: https://www.mdpi.com/1718-7729/29/7/373
5. “Minimally Invasive Surgery for Cervical Cancer in Light of the LACC Trial: What Have We Learned?”
by Omar Touhami and Marie Plante
Curr. Oncol. 2022, 29(2), 1093–1106; https://doi.org/10.3390/curroncol29020093
Available online: https://www.mdpi.com/1718-7729/29/2/93
6. “A Qualitative Study of Patient and Healthcare Provider Perspectives on Building Multiphasic Exercise Prehabilitation into the Surgical Care Pathway for Head and Neck Cancer”
by Julia T. Daun, Rosie Twomey, Joseph C. Dort, Lauren C. Capozzi, Trafford Crump, George J. Francis, T. Wayne Matthews, Shamir P. Chandarana, Robert D. Hart, Christiaan Schrag et al.
Curr. Oncol. 2022, 29(8), 5942–5954; https://doi.org/10.3390/curroncol29080469
Available online: https://www.mdpi.com/1718-7729/29/8/469
7. “Surgical Treatment of Distal Cholangiocarcinoma”
by Leva Gorji and Eliza W. Beal
Curr. Oncol. 2022, 29(9), 6674–6687; https://doi.org/10.3390/curroncol29090524
Available online: https://www.mdpi.com/1718-7729/29/9/524
8. “Upfront Chemotherapy Followed by Stereotactic Body Radiation Therapy with or without Surgery in Older Patients with Localized Pancreatic Cancer: A Single Institution Experience and Review of the Literature”
by Abhinav V. Reddy, Shuchi Sehgal, Colin S. Hill, Lei Zheng, Jin He, Joseph M. Herman, Jeffrey Meyer and Amol K. Narang
Curr. Oncol. 2022, 29(1), 308–320; https://doi.org/10.3390/curroncol29010028
Available online: https://www.mdpi.com/1718-7729/29/1/28
9. “The Role of Surgical Approaches in the Multi-Modal Management of Adult Craniopharyngiomas”
by Christopher S. Hong and Sacit Bulent Omay
Curr. Oncol. 2022, 29(3), 1408–1421; https://doi.org/10.3390/curroncol29030118
Available online: https://www.mdpi.com/1718-7729/29/3/118
10. “Surgical Management of Craniovertebral Junction Schwannomas: A Systematic Review”
by Paolo Palmisciano, Gianluca Ferini, Gina Watanabe, Andie Conching, Christian Ogasawara, Gianluca Scalia, Othman Bin-Alamer, Ali S. Haider, Maurizio Passanisi, Rosario Maugeri et al.
Curr. Oncol. 2022, 29(7), 4842–4855; https://doi.org/10.3390/curroncol29070384
Available online: https://www.mdpi.com/1718-7729/29/7/384
25 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Palliative and Supportive Care”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Palliative and Supportive Care” below:
1. “Satisfaction with Telemedicine for Cancer Pain Management: A Model of Care and Cross-Sectional Patient Satisfaction Study”
by Marco Cascella, Sergio Coluccia, Mariacinzia Grizzuti, Maria Cristina Romano, Gennaro Esposito, Anna Crispo and Arturo Cuomo
Curr. Oncol. 2022, 29(8), 5566–5578; https://doi.org/10.3390/curroncol29080439
Available online: https://www.mdpi.com/1718-7729/29/8/439
2. “Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care”
by Brandon S. Sheffield, Andrea Beharry, Joanne Diep, Kirstin Perdrizet, Marco A. J. Iafolla, William Raskin, Shaan Dudani, Mary Anne Brett, Blerta Starova, Brian Olsen et al.
Curr. Oncol. 2022, 29(3), 1326–1334; https://doi.org/10.3390/curroncol29030113
Available online: https://www.mdpi.com/1718-7729/29/3/113
3. “Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Tertiary Care Center in North-West Italy”
by Davide Giuseppe Ribaldone, Gian Paolo Caviglia, Silvia Gaia, Emanuela Rolle, Alessandra Risso, Daniela Campion, Paola Rita Brunocilla, Giorgio Maria Saracco and Patrizia Carucci
Curr. Oncol. 2022, 29(3), 1422–1429; https://doi.org/10.3390/curroncol29030119
Available online: https://www.mdpi.com/1718-7729/29/3/119
4. “The Psychosocial Impact of COVID-19 on Older Adults with Cancer: A Rapid Review”
by Ridhi Verma, Heather M. Kilgour and Kristen R. Haase
Curr. Oncol. 2022, 29(2), 589–601; https://doi.org/10.3390/curroncol29020053
Available online: https://www.mdpi.com/1718-7729/29/2/53
5. “The Use of Virtual Care in Patients with Hematologic Malignancies: A Scoping Review”
by Adam Suleman, Abi Vijenthira, Alejandro Berlin, Anca Prica and Danielle Rodin
Curr. Oncol. 2022, 29(2), 892–900; https://doi.org/10.3390/curroncol29020076
Available online: https://www.mdpi.com/1718-7729/29/2/76
6. “Patient and Physician Satisfaction with Telemedicine in Cancer Care in Saskatchewan: A Cross-Sectional Study”
by Hurria Gondal, Tahir Abbas, Heather Choquette, Duc Le, Haji Ibraheem Chalchal, Nayyer Iqbal and Shahid Ahmed
Curr. Oncol. 2022, 29(6), 3870–3880; https://doi.org/10.3390/curroncol29060309
Available online: https://www.mdpi.com/1718-7729/29/6/309
7. “Tailoring the Evidence for Exercise Oncology within Breast Cancer Care”
by Chad W. Wagoner, Lauren C. Capozzi and S. Nicole Culos-Reed
Curr. Oncol. 2022, 29(7), 4827–4841; https://doi.org/10.3390/curroncol29070383
Available online: https://www.mdpi.com/1718-7729/29/7/383
8. “Treatment of Older Adult Patients with Glioblastoma: Moving towards the Inclusion of a Comprehensive Geriatric Assessment for Guiding Management”
by Manik Chahal, Brian Thiessen and Caroline Mariano
Curr. Oncol. 2022, 29(1), 360–376; https://doi.org/10.3390/curroncol29010032
Available online: https://www.mdpi.com/1718-7729/29/1/32
9. “Challenges in Geriatric Oncology—A Surgeon’s Perspective”
by Ruth Parks and Kwok-Leung Cheung
Curr. Oncol. 2022, 29(2), 659–674; https://doi.org/10.3390/curroncol29020058
Available online: https://www.mdpi.com/1718-7729/29/2/58
10. “Understanding the Post-Treatment Concerns of Cancer Survivors with Five Common Cancers: Exploring the Alberta Results from the Pan-Canadian Transitions Study”
by Claire Link, Andrea DeIure and Linda Watson
Curr. Oncol. 2022, 29(4), 2662–2680; https://doi.org/10.3390/curroncol29040218
Available online: https://www.mdpi.com/1718-7729/29/4/218
22 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Cell Therapy”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Cell Therapy” below:
1. “A Portrait of SARS-CoV-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature”
by Adrian J. M. Bailey, Aidan M. Kirkham, Madeline Monaghan, Risa Shorr, C. Arianne Buchan, Christopher Bredeson and David S. Allan
Curr. Oncol. 2022, 29(1), 337-349; https://doi.org/10.3390/curroncol29010030
Available online: https://www.mdpi.com/1718-7729/29/1/30
2. “A Scoping Review on Outcomes and Outcome Measurement Instruments in Rehabilitative Interventions for Patients with Haematological Malignancies Treated with Allogeneic Stem Cell Transplantation”
by Anastasios I. Manettas, Panagiotis Tsaklis, Dario Kohlbrenner and Lidwine B. Mokkink
Curr. Oncol. 2022, 29(7), 4998-5025; https://doi.org/10.3390/curroncol29070397
Available online: https://www.mdpi.com/1718-7729/29/7/397
3. “Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada”
by Graeme Ball, Christopher Lemieux, David Cameron and Matthew D. Seftel
Curr. Oncol. 2022, 29(3), 2021-2045; https://doi.org/10.3390/curroncol29030164
Available online: https://www.mdpi.com/1718-7729/29/3/164
4. “Abstracts of the Cell Therapy Transplant Canada 2022 Annual Conference”
by Stephanie A. Maier, Tobias Berg, Susan Berrigan, Jonathan Bramson, Chris Bredeson, Guy Cantin, Andrew Daly, Gwynivere A. Davies, Mahmoud Elsawy, Alejandro Garcia-Horton et al.
Curr. Oncol. 2022, 29(12), 9970-10017; https://doi.org/10.3390/curroncol29120783
Available online: https://www.mdpi.com/1718-7729/29/12/783
5. “Access to Hematopoietic Stem Cell Transplant in Canada for Patients with Acute Myeloid”
by Oluwatobiloba Morakinyo, Oliver Bucher and Kristjan Paulson
Curr. Oncol. 2022, 29(8), 5198-5208; https://doi.org/10.3390/curroncol29080412
Available online: https://www.mdpi.com/1718-7729/29/8/412
6. “Donor Age and Non-Relapse Mortality: Study of Their Association after HLA-Matched Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome”
by Yasmine Kadri, Michelle Phan, Nadia Bambace, Léa Bernard, Sandra Cohen, Jean-Sébastien Delisle, Thomas Kiss, Sylvie Lachance, Denis-Claude Roy, Guy Sauvageau et al.
Curr. Oncol. 2022, 29(8), 5955-5962; https://doi.org/10.3390/curroncol29080470
Available online: https://www.mdpi.com/1718-7729/29/8/470
22 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Medical Oncology”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Medical Oncology” below:
1. “Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria”
by Philippe d’Abadie, Stephan Walrand, Renaud Lhommel, Michel Hesse, Ivan Borbath and François Jamar
Curr. Oncol. 2022, 29(4), 2422-2434; https://doi.org/10.3390/curroncol29040196
Available online: https://www.mdpi.com/1718-7729/29/4/196
2. “Health Literacy and Clinical Trial Participation in French Cancer Patients: A National Survey”
by Youssoufa M. Ousseine, Anne-Déborah Bouhnik and Julien Mancini
Curr. Oncol. 2022, 29(5), 3118-3129; https://doi.org/10.3390/curroncol29050253
Available online: https://www.mdpi.com/1718-7729/29/5/253
3. “5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice”
by Takuo Yamai, Kenji Ikezawa, Yasuharu Kawamoto, Takeru Hirao, Sena Higashi, Kazuma Daiku, Shingo Maeda, Yutaro Abe, Makiko Urabe, Yugo Kai et al.
Curr. Oncol. 2022, 29(4), 2644-2649; https://doi.org/10.3390/curroncol29040216
Available online: https://www.mdpi.com/1718-7729/29/4/216
4. “Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma”
by Randeep Sangha, Neal M. Davies, Afshin Namdar, Michael Chu, Jennifer Spratlin, Erwan Beauchamp, Luc G. Berthiaume and John R. Mackey
Curr. Oncol. 2022, 29(3), 1939-1946; https://doi.org/10.3390/curroncol29030158
Available online: https://www.mdpi.com/1718-7729/29/3/158
5. “Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events”
by Arezou Teimouri, Laura V. Minard, Samantha N. Scott, Amanda Daniels and Stephanie Snow
Curr. Oncol. 2022, 29(5), 3104-3117; https://doi.org/10.3390/curroncol29050252
Available online: https://www.mdpi.com/1718-7729/29/5/252
6. “Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline”
by Phillip Blanchette, Duvaraga Sivajohanathan, John Bartlett, Andrea Eisen, Harriet Feilotter, Rossanna Pezo, Gulisa Turashvili and Phillip Williams
Curr. Oncol. 2022, 29(4), 2599-2615; https://doi.org/10.3390/curroncol29040213
Available online: https://www.mdpi.com/1718-7729/29/4/213
7. “Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study”
by Alexandra Moskalewic, Amy Di Tomaso, Jacob J. Kachura, Samantha Scime, Rosane Nisenbaum, Ronita Lee, Rashida Haq, Christine Derzko and Christine Brezden-Masley
Curr. Oncol. 2022, 29(3), 1813-1827; https://doi.org/10.3390/curroncol29030149
Available online: https://www.mdpi.com/1718-7729/29/3/149
8. “The Clinical Impact of Neoadjuvant Endocrine Treatment on Luminal-like Breast Cancers and Its Prognostic Significance: Results from a Single-Institution Prospective Cohort Study”
by Covadonga Martí, Laura Yébenes, José María Oliver, Elisa Moreno, Laura Frías, Alberto Berjón, Adolfo Loayza, Marcos Meléndez, María José Roca, Vicenta Córdoba et al.
Curr. Oncol. 2022, 29(4), 2199-2210; https://doi.org/10.3390/curroncol29040179
Available online: https://www.mdpi.com/1718-7729/29/4/179
9. “Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists”
by Irena Druce, Karine Tawagi, Julie L. V. Shaw, Andrea Ibrahim, Heather Lochnan and Michael Ong
Curr. Oncol. 2022, 29(7), 4665-4677; https://doi.org/10.3390/curroncol29070370
Available online: https://www.mdpi.com/1718-7729/29/7/370
15 September 2023
Current Oncology | World Lymphoma Awareness Day in 2023—“We Can’t Wait”

World Lymphoma Awareness Day (WLAD) takes place annually on September 15th. It is organized by the Lymphoma Coalition and was established in 2004 with the purpose of promoting public understanding of the various subtypes of lymphoma. Its primary objectives include educating people about recognizing symptoms, encouraging early diagnosis, and emphasizing the importance of timely treatment.
For World Lymphoma Awareness Day 2023, Current Oncology (ISSN: 1718-7729) has gathered open access academic research on the topic of lymphoma. We hope to share new scientific knowledge in the field of lymphoma with the world on this special day.
1. “CD5-Negative, CD10-Negative Low-Grade B-Cell Lymphoproliferative Disorders of the Spleen”
by John J. Schmieg, Jeannie M. Muir, Nadine S. Aguilera and Aaron Auerbach
Curr. Oncol. 2021, 28(6), 5124–5147; https://doi.org/10.3390/curroncol28060430
Available online: https://www.mdpi.com/1718-7729/28/6/430
2. “How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen”
by José Cabeçadas, Victor E. Nava, Joao L. Ascensao and Maria Gomes da Silva
Curr. Oncol. 2021, 28(6), 4611–4633; https://doi.org/10.3390/curroncol28060390
Available online: https://www.mdpi.com/1718-7729/28/6/390
3. “A Review on Splenic Diffuse Red Pulp Small B-Cell Lymphoma”
by Elif Yilmaz, Arashpreet Chhina, Victor E. Nava and Anita Aggarwal
Curr. Oncol. 2021, 28(6), 5148–5154; https://doi.org/10.3390/curroncol28060431
Available online: https://www.mdpi.com/1718-7729/28/6/431
4. “Low-Grade Primary Splenic CD10-Positive Small B-Cell Lymphoma/Follicular Lymphoma”
by Rami Abdulbaki, Parastou Tizro, Victor E. Nava, Maria Gomes da Silva and João L. Ascensão
Curr. Oncol. 2021, 28(6), 4821–4831; https://doi.org/10.3390/curroncol28060407
Available online: https://www.mdpi.com/1718-7729/28/6/407
5. “Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology”
by Evgenii Shumilov, Paolo Mazzeo, Martin S. Zinkernagel, Myriam Legros, Naomi Porret, Lorenz Romagna, Detlef Haase, Georg Lenz, Urban Novak, Yara Banz et al.
Curr. Oncol. 2022, 29(2), 766–776; https://doi.org/10.3390/curroncol29020065
Available online: https://www.mdpi.com/1718-7729/29/2/65
6. “Intravascular Large B-Cell Lymphoma: A Review with a Focus on the Prognostic Value of Skin Involvement”
by Thomas Breakell, Heidi Waibel, Stefan Schliep, Barbara Ferstl, Michael Erdmann, Carola Berking and Markus V. Heppt
Curr. Oncol. 2022, 29(5), 2909–2919; https://doi.org/10.3390/curroncol29050237
Available online: https://www.mdpi.com/1718-7729/29/5/237
7. “Management of Marginal Zone Lymphoma: A Canadian Perspective”
by Anthea Peters, Mary-Margaret Keating, Anna Nikonova, Sarah Doucette and Anca Prica
Curr. Oncol. 2023, 30(2), 1745–1759; https://doi.org/10.3390/curroncol30020135
Available online: https://www.mdpi.com/1718-7729/30/2/135
8. “Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada”
by Graeme Ball, Christopher Lemieux, David Cameron and Matthew D. Seftel
Curr. Oncol. 2022, 29(3), 2021–2045; https://doi.org/10.3390/curroncol29030164
Available online: https://www.mdpi.com/1718-7729/29/3/164
9. “Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma”
by Randeep Sangha, Neal M. Davies, Afshin Namdar, Michael Chu, Jennifer Spratlin, Erwan Beauchamp, Luc G. Berthiaume and John R. Mackey
Curr. Oncol. 2022, 29(3), 1939–1946; https://doi.org/10.3390/curroncol29030158
Available online: https://www.mdpi.com/1718-7729/29/3/158
10. “Novel Mutations in a Lethal Case of Lymphomatous Adult T Cell Lymphoma with Cryptic Myocardial Involvement”
by Taraneh Hashemi Zonouz, Rami Abdulbaki, Bidhan C. Bandyopadhyay and Victor E. Nava
Curr. Oncol. 2021, 28(1), 818–824; https://doi.org/10.3390/curroncol28010079
Available online: https://www.mdpi.com/1718-7729/28/1/79